Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
137 hedge funds and large institutions have $643M invested in Intra-Cellular Therapies Inc. in 2017 Q3 according to their latest regulatory filings, with 47 funds opening new positions, 43 increasing their positions, 23 reducing their positions, and 10 closing their positions.
370% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 10
87% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 23
67% more capital invested
Capital invested by funds: $385M → $643M (+$258M)
37% more funds holding
Funds holding: 100 → 137 (+37)
51% less call options, than puts
Call options by funds: $6.91M | Put options by funds: $14.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$21.3M |
| 2 |
Millennium Management
New York
|
+$20.3M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$14.5M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$13.9M |
| 5 |
PA
Perceptive Advisors
New York
|
+$13.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$19.5M |
| 2 |
BlackRock
New York
|
-$7.95M |
| 3 |
Goldman Sachs
New York
|
-$5.18M |
| 4 |
State Street
Boston,
Massachusetts
|
-$3.91M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$2.48M |
ITCI Hedge Fund Activity: Q3 2017 in Review
137 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q3 2017, worth a combined $643M — up 67% from $385M a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new ITCI positions and 10 closed out — a net gain of 37 holders — while 43 added to existing stakes and 23 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $21.3M. The largest seller was Citadel Advisors, cutting an estimated $19.5M.
- 137 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q3 2017, up from 100 in Q2 2017.
- Funds reported $643M of Intra-Cellular Therapies Inc. stock for Q3 2017, up 67% quarter-over-quarter.
- 47 funds opened new Intra-Cellular Therapies Inc. positions in Q3 2017 and 10 closed out, a net change of +37 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q3 2017 was Fidelity Investments, an estimated $21.3M added.
- The largest Intra-Cellular Therapies Inc. seller in Q3 2017 was Citadel Advisors, an estimated $19.5M sold.
Based on aggregated 13F filings for Q3 2017.